Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Hims & Hers Health, Inc.
HIMS
NYSE·Healthcare·Medical - Equipment & Services·Mkt cap $8.4B
$36.80
▼ -2.05%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$13.74 - $70.43
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 20.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
6 reasons
- Integrated telehealth platform with licensed provider network reducing access barriers
- Direct-to-consumer model enabling higher margins and customer data insights
- Diversified product portfolio across wellness categories driving cross-selling opportunities
- Brand recognition in digital health with strong millennial and Gen Z adoption
- Proprietary technology platform and mobile app creating switching costs
- Recurring revenue model through prescription refills and subscription services
Bear Case
2 risks
- High volatility (beta 2.4). Larger-than-normal price swings expected.
- Extreme premium - high expectations embedded
Growth
Turning profitable
Expanding telehealth adoption and normalization of virtual healthcare consultations
Value
Extreme premium - high expectations embedded
Momentum
Hot
+96.3% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying HIMS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 11, 2026
Reported EPS of -$0.40 vs $0.04 consensus (-1100.0% surprise). Revenue of $608.1M vs $616.8M expected (-1.4%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-1100.0%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+95%
+111%
+73%
+49%
+28%
+4%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$315.6M
$401.6M
$481.1M
$586.0M
$544.8M
$599.0M
$617.8M
$608.1M
Margins · last 8Q
Gross
—
Operating
—
Profit
-15.2%
Wall Street consensus
12 analysts · 25% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
25%
Hold
75%
Sell
0%
Median Price Target
$25.00
▼ -32.1% vs $36.80
Latest: Barclays · Jun 17, 2026
5 analysts covering
vs Industry
How HIMS stacks vs Medical - Equipment & Services
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related